Fibrogen continues plunge amid FDA panel vote on kidney drug roxadustat

seekingalpha2021-07-16

Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee voted against recommending approval of roxadustat developed by FibroGen and AstraZeneca (AZN-0.3%) ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Freedosmsk
2021-07-18
Freedosmsk
Like 👍
KS_Lee
2021-07-17
KS_Lee
Maybe some under hands politics at play.
T20211126001
2021-07-17
T20211126001
Like
Bull1973
2021-07-17
Bull1973
Oki
CM_clement
2021-07-17
CM_clement
Other countries have approved....why FDA declined?
- Bull1973:
  Ok
- Derlin:
  Ok
Darryl0120
2021-07-17
Darryl0120
6666666666

发表看法

796

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1179740731?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-16 23:09","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1179740731","market":"us","top_or_hot":-1,"title":"Fibrogen continues plunge amid FDA panel vote on kidney drug roxadustat","media":"seekingalpha","content":"<div>\n<p>Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee voted against recommending approval of roxadustat developed by FibroGen and AstraZeneca (AZN-0.3%) ...</p>\n\n<a href=\"https://seekingalpha.com/news/3716007-fibrogen-continues-plunge-amid-fda-panel-vote-on-kidney-drug-roxadustat\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fibrogen continues plunge amid FDA panel vote on kidney drug roxadustat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibrogen continues plunge amid FDA panel vote on kidney drug roxadustat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 23:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3716007-fibrogen-continues-plunge-amid-fda-panel-vote-on-kidney-drug-roxadustat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee voted against recommending approval of roxadustat developed by FibroGen and AstraZeneca (AZN-0.3%) ...</p>\n\n<a href=\"https://seekingalpha.com/news/3716007-fibrogen-continues-plunge-amid-fda-panel-vote-on-kidney-drug-roxadustat\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FGEN","symbol_name":"FibroGen, Inc","start_time":0,"source_url":"https://seekingalpha.com/news/3716007-fibrogen-continues-plunge-amid-fda-panel-vote-on-kidney-drug-roxadustat","article_id":"1179740731","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179740731","pubTimestamp":1626448147,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FGEN":"FibroGen, Inc"},"translate_title":"FDA小组对肾脏药物罗沙度司他的投票中，纤维原继续暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FGEN":0.9},"content_text":"Shares of Fibrogen (FGEN-45.3%) are down sharply in morning trading after an FDA advisory committee voted against recommending approval of roxadustat developed by FibroGen and AstraZeneca (AZN-0.3%) for the treatment of adults with anemia due to chronic kidney disease.\nLate last month, a panel of the European Medicines Agency endorsed the approval ofroxadustat for the indication.\nThe drug is already approved in China and Japan.\nFibrogen's only other candidate is pamrevlumab in phase 3 pancreatic cancer, Duchenne muscular dystrophy, and idiopathic pulmonary fibrosis.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":173986204,"gmtCreate":1626599868508,"gmtModify":1633925560105,"author":{"id":"3581979450929071","authorId":"3581979450929071","name":"Freedosmsk","avatar":"https://static.tigerbbs.com/d4a0c9ddf13765c4e7249deeb73cbb10","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like 👍&nbsp;","listText":"Like 👍&nbsp;","text":"Like 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173986204","repostId":1179740731,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179299408,"gmtCreate":1626528652004,"gmtModify":1633926036424,"author":{"id":"3579578865458065","authorId":"3579578865458065","name":"KS_Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Maybe some under hands politics at play.&nbsp;","listText":"Maybe some under hands politics at play.&nbsp;","text":"Maybe some under hands politics at play.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179299408","repostId":1179740731,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179854411,"gmtCreate":1626507191633,"gmtModify":1633926141699,"author":{"id":"3575955563694893","authorId":"3575955563694893","name":"T20211126001","avatar":"https://static.tigerbbs.com/42cf33544f719c12b3a2aa7e6bd084b1","vip":1,"crmLevel":8,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179854411","repostId":1179740731,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179888716,"gmtCreate":1626503031035,"gmtModify":1631892631128,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Oki","listText":"Oki","text":"Oki","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179888716","repostId":1179740731,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179835821,"gmtCreate":1626501308663,"gmtModify":1633926183919,"author":{"id":"3575978693829354","authorId":"3575978693829354","name":"CM_clement","avatar":"https://static.tigerbbs.com/fdbebfac76fb8dfe00958a92cdb8d706","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Other countries have approved....why FDA declined?","listText":"Other countries have approved....why FDA declined?","text":"Other countries have approved....why FDA declined?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/179835821","repostId":1179740731,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5247293,"gmtCreate":1626503023933,"gmtModify":1635227280401,"authorId":3584680402793671,"author":{"id":3584680402793671,"authorId":3584680402793671,"name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179835821,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5248049,"gmtCreate":1626513830434,"gmtModify":1635227224759,"authorId":3555938823736400,"author":{"id":3555938823736400,"authorId":3555938823736400,"name":"Derlin","avatar":"https://static.tigerbbs.com/c7a371f3d4269b1475b05c66bce026d0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179835821,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":179341520,"gmtCreate":1626488729360,"gmtModify":1631892436166,"author":{"id":"3586053494877214","authorId":"3586053494877214","name":"Darryl0120","avatar":"https://static.tigerbbs.com/7d228e686d5afa7f83063b50acd5fed7","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"6666666666","listText":"6666666666","text":"6666666666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179341520","repostId":1179740731,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":796,"commentSize":70,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179740731"}